tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2023 Jun 12;29(7).
doi: 10.3201/eid2907.230198. Online ahead of print.
Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, Canada
Rajesh Abraham Jacob, Ali Zhang, Hannah O Ajoge, Michael R D'Agostino, Kuganya Nirmalarajah, Altynay Shigayeva, Wael L Demian, Sheridan J C Baker, Hooman Derakhshani, Laura Rossi, Jalees A Nasir, Emily M Panousis, Ahmed N Draia, Christie Vermeiren, Jodi Gilchrist, Nicole Smieja, David Bulir, Marek Smieja, Michael G Surette, Andrew G McArthur, Allison J McGeer, Samira Mubareka, Arinjay Banerjee, Matthew S Miller, Karen Mossman
Isolating and characterizing emerging SARS-CoV-2 variants is key to understanding virus pathogenesis. In this study, we isolated samples of the SARS-CoV-2 R.1 lineage, categorized as a variant under monitoring by the World Health Organization, and evaluated their sensitivity to neutralizing antibodies and type I interferons. We used convalescent serum samples from persons in Canada infected either with ancestral virus (wave 1) or the B.1.1.7 (Alpha) variant of concern (wave 3) for testing neutralization sensitivity. The R.1 isolates were potently neutralized by both the wave 1 and wave 3 convalescent serum samples, unlike the B.1.351 (Beta) variant of concern. Of note, the R.1 variant was significantly more resistant to type I interferons (IFN-α/β) than was the ancestral isolate. Our study demonstrates that the R.1 variant retained sensitivity to neutralizing antibodies but evolved resistance to type I interferons. This critical driving force will influence the trajectory of the pandemic.
Keywords: COVID-19; Canada; N501Y spike; SARS-CoV-2; VoC; VuM; coronavirus disease; neutralizing antibodies; respiratory infections; severe acute respiratory syndrome coronavirus 2; type I interferons; variant under monitoring; variants of concern; viruses; zoonoses.
. 2023 Jun 12;29(7).
doi: 10.3201/eid2907.230198. Online ahead of print.
Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, Canada
Rajesh Abraham Jacob, Ali Zhang, Hannah O Ajoge, Michael R D'Agostino, Kuganya Nirmalarajah, Altynay Shigayeva, Wael L Demian, Sheridan J C Baker, Hooman Derakhshani, Laura Rossi, Jalees A Nasir, Emily M Panousis, Ahmed N Draia, Christie Vermeiren, Jodi Gilchrist, Nicole Smieja, David Bulir, Marek Smieja, Michael G Surette, Andrew G McArthur, Allison J McGeer, Samira Mubareka, Arinjay Banerjee, Matthew S Miller, Karen Mossman
- PMID: 37308158
- DOI: 10.3201/eid2907.230198
Isolating and characterizing emerging SARS-CoV-2 variants is key to understanding virus pathogenesis. In this study, we isolated samples of the SARS-CoV-2 R.1 lineage, categorized as a variant under monitoring by the World Health Organization, and evaluated their sensitivity to neutralizing antibodies and type I interferons. We used convalescent serum samples from persons in Canada infected either with ancestral virus (wave 1) or the B.1.1.7 (Alpha) variant of concern (wave 3) for testing neutralization sensitivity. The R.1 isolates were potently neutralized by both the wave 1 and wave 3 convalescent serum samples, unlike the B.1.351 (Beta) variant of concern. Of note, the R.1 variant was significantly more resistant to type I interferons (IFN-α/β) than was the ancestral isolate. Our study demonstrates that the R.1 variant retained sensitivity to neutralizing antibodies but evolved resistance to type I interferons. This critical driving force will influence the trajectory of the pandemic.
Keywords: COVID-19; Canada; N501Y spike; SARS-CoV-2; VoC; VuM; coronavirus disease; neutralizing antibodies; respiratory infections; severe acute respiratory syndrome coronavirus 2; type I interferons; variant under monitoring; variants of concern; viruses; zoonoses.